APA

Do D. V., Sepah Y. J., Boyer D., Callanan D., Gallemore R., Bennett M., Marcus D. M., Halperin L., Sadiq M. A., Rajagopalan N., Campochiaro P. A. & Nguyen Q. D. (20160712). Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). : Eye (London, England).

Chicago

Do D V, Sepah Y J, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D M, Halperin L, Sadiq M A, Rajagopalan N, Campochiaro P A and Nguyen Q D. 20160712. Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). : Eye (London, England).

Harvard

Do D. V., Sepah Y. J., Boyer D., Callanan D., Gallemore R., Bennett M., Marcus D. M., Halperin L., Sadiq M. A., Rajagopalan N., Campochiaro P. A. and Nguyen Q. D. (20160712). Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). : Eye (London, England).

MLA

Do D V, Sepah Y J, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D M, Halperin L, Sadiq M A, Rajagopalan N, Campochiaro P A and Nguyen Q D. Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose). : Eye (London, England). 20160712.